| __timestamp | Axsome Therapeutics, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 612613000000 |
| Thursday, January 1, 2015 | 2419289 | 650773000000 |
| Friday, January 1, 2016 | 6343648 | 619061000000 |
| Sunday, January 1, 2017 | 7206691 | 628106000000 |
| Monday, January 1, 2018 | 9351522 | 717599000000 |
| Tuesday, January 1, 2019 | 13598030 | 964737000000 |
| Wednesday, January 1, 2020 | 28896749 | 875663000000 |
| Friday, January 1, 2021 | 66646205 | 886361000000 |
| Saturday, January 1, 2022 | 159253661 | 997309000000 |
| Sunday, January 1, 2023 | 323123000 | 1053819000000 |
| Monday, January 1, 2024 | 411359000 | 1053819000000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and Axsome Therapeutics, Inc. from 2014 to 2023. Takeda, a global leader, consistently reported SG&A expenses in the range of hundreds of billions, peaking at approximately 1.05 trillion in 2023. In contrast, Axsome, a burgeoning player, saw a dramatic increase in SG&A expenses, skyrocketing from a modest 1.4 million in 2014 to over 320 million by 2023. This represents a staggering growth of over 22,000%. While Takeda's expenses reflect its expansive operations, Axsome's surge highlights its aggressive growth strategy. Notably, data for 2024 is incomplete, indicating potential shifts in the financial landscape. This comparison underscores the diverse strategies and scales within the pharmaceutical sector.
Selling, General, and Administrative Costs: AstraZeneca PLC vs Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited Trends and Insights
GSK plc vs Axsome Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs CymaBay Therapeutics, Inc.
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Takeda Pharmaceutical Company Limited and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Mesoblast Limited Trends and Insights
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Catalent, Inc. or Axsome Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and Axsome Therapeutics, Inc.